Shareholders to Vote on Reverse Stock Split to Avoid Nasdaq Delisting Amidst Multiple Non-Compliance Issues
DYAI sits 21% above its 52-week low of $0.655 on light trading volume (0.2× avg).
Summary
Dyadic International will hold its annual meeting on June 18, 2026, where shareholders will vote on authorizing a reverse stock split (2:1 to 10:1) to prevent Nasdaq delisting due to multiple non-compliance issues, including the minimum bid price rule.
Key Events · Corporate Governance and Compliance · DYAI
-
Reverse Stock Split Authorization Proposed
Shareholders will vote on authorizing the Board to implement a reverse stock split with a ratio between 2:1 and 10:1. This is a direct response to the company's non-compliance with Nasdaq's $1.00 minimum bid price rule.
-
Multiple Nasdaq Non-Compliance Issues
The company is not only non-compliant with the minimum bid price rule but also with other Nasdaq listing standards, such as minimum shareholders' equity or market value of listed securities, indicating broader financial challenges.
-
Related-Party Convertible Note Amendment
An amendment to $5.09 million in related-party convertible notes in December 2025 reduced the conversion price to $1.05 per share (from previous higher prices), potentially favoring insiders and increasing future dilution.
-
Section 16(a) Filing Delinquency Noted
The Francisco Trust, a 10% owner, failed to file a Form 4 to disclose the December 2025 amendment to its convertible note, indicating a compliance lapse.
Analysis · DYAI · Life Sciences
Dyadic International is seeking shareholder authorization for a reverse stock split, with a ratio between 2:1 and 10:1, to address its non-compliance with Nasdaq's $1.00 minimum bid price rule. The company faces a June 17, 2026, deadline and intends to seek an extension until December 15, 2026. This proposal is critical as delisting would severely impact the company's liquidity and investor confidence, especially given its nano-cap status. The filing also reveals the company is not in compliance with other Nasdaq listing standards, including minimum shareholders' equity or market value of listed securities, with a compliance plan due by September 23, 2026. Furthermore, the proxy details a related-party convertible note amendment from December 2025, which reduced the conversion price to $1.05 per share, favoring insiders and potentially increasing future dilution. The Francisco Trust, a 10% owner, was delinquent in filing a Form 4 for this amendment.
At the time of this filing, DYAI was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.8M. The 52-week trading range was $0.65 to $1.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.